Claims for Patent: 6,180,110

Summary for Patent: 6,180,110

Title:	Attenuated hepatitis a virus vaccine which grows in MRC-5 cells
Abstract:	A live hepatitis A virus (HAV) adapted to grow in MRC-5 cells is described, the HAV preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation. Methods for adapting HAV to grow in MRC-5 cells, vaccine compositions comprising the attenuated HAV, and methods of vaccinating humans against HAV infection are also described.
Inventor(s):	Funkhouser; Ann W. (Ellicott City, MD), Emerson; Suzanne U. (Rockville, MD), Purcell; Robert H. (Boyds, MD), D\'Hondt; Eric (Ottenburg, BE)
Assignee:	The United States of America as represented by the Department of Health and Human Services (Washington, DC)
Application Number:	08/397,232
Patent Claims:	1. A hepatitis A virus HAV 4380 having Institute Pasteur Accession No. I-936, where said virus is characterized by the ability to grow in MRC-5 cells. 2. A vaccine composition useful for protecting humans or primates against hepatitis A, said vaccine comprising the hepatitis A virus of claim 1. 3. A method for protecting a human or primate against hepatitis A, said method comprising administering the vaccine of claim 1 to said human or primate in an amount effective to protect said human or primate against hepatitis A. 4. A hepatitis A virus encoded by a nucleic acid molecule having the nucleic acid sequence according to SEQ ID NO:3. 5. A hepatitis A vaccine comprising the virus of claim 4. 6. A method for protecting a human or primate against hepatitis A, said method comprising administering the vaccine of claim 5 to said human or primate in an amount effective to protect said human or primate against hepatitis A.

Details for Patent 6,180,110

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Biologicals	HAVRIX	hepatitis a vaccine inactivated	Injection	103475	02/22/1995		2018-01-30